フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Sandoz announces nominations to the Board of Directors and leadership change Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market MEDIA RELEASE CIMERLI®*, a...
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs Ad hoc announcement pursuant...
Sandoz announces changes in the Board of Directors Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany Ad hoc announcement pursuant to art. 53 SIX...
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market Ad hoc announcement pursuant to...
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care Biosimilar Hyrimoz®...
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany Investment of EUR 175 million...
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN ...
Sandoz successfully issues CHF 750 million in inaugural bonds Highly successful inaugural CHF senior bonds priced earlier todayTwo tranches...
Sandoz reports year-to-date sales for the first nine months of 2023 Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約